Posts

AstraZeneca wins FDA nod for first‑in‑class blood pressure pill Baxfendy

on

AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too

on

"A Bit of a Surprise": Kardigan's Tonlamarsen Shows No Blood Pressure Benefit from Repeat Dosing in Phase 2 Trial

on

FW In Conversation: Mineralys CEO Jon Congleton on Reviving Hypertension Innovation and Lorundrostat's Best-in-Class Potential

on

FDA Rejects Relacorilant for Cushing's Syndrome High Blood Pressure

on

AstraZeneca gears up for FDA filing after baxdrostat's phase 3 hypertension success

on

Roche and Alnylam Push Zilebesiran into Phase III Trial Despite Mixed Phase II Hypertension Data

on

AstraZeneca’s Baxdrostat Achieves Pivotal Phase 3 Success for Hypertension, Validating $1.3B CinCor Acquisition

on

Chronic care startup Omada Health files to go public

on

Mineralys Phase 3 blood pressure pill data support potential FDA approval

on

Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug

on

NFL Legend Jerome Bettis Joins CDC Foundation's "Live to the Beat" Campaign to Tackle Heart Health in Black Community

on